Description

Tirzepatide works by mimicking the activity of natural incretin hormones released after eating. By activating GLP-1 and GIP receptors, it helps increase insulin secretion, reduce glucagon levels, slow gastric emptying, and decrease appetite. These effects support improved glucose regulation and reduced caloric intake.

Clinical research has shown that tirzepatide can produce substantial weight loss and improvements in metabolic markers, including blood sugar and insulin sensitivity. Because it targets two incretin pathways simultaneously, it is often described as a dual-agonist metabolic peptide designed to support both weight management and glycemic control.